All News

2020

June

Media Release / Jun 29, 2020

Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14

Read More
Media Release / Jun 25, 2020

Novartis Resolves Legacy FCPA Investigations

Read More
Media Release / Jun 24, 2020

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges

Read More
Media Release / Jun 18, 2020

Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania

Read More
Media Release / Jun 11, 2020

US FDA approves updated Novartis Beovu® label, to include additional safety information

Read More

May

Media Release / May 29, 2020

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

Read More
Media Release / May 14, 2020

Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms

Read More
Media Release / May 06, 2020

Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

Read More

April

Novartis associates working in a cell and gene laboratory in Stein, Switzerland
Featured News / Apr 28, 2020

Novartis Financial Results – Q1 2020

Novartis announced the company’s financial results for the first quarter of 2020.

Read More
Media Release / Apr 28, 2020

Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More